PMID- 23824498
OWN - NLM
STAT- MEDLINE
DCOM- 20140505
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 62
IP  - 10
DP  - 2013 Oct
TI  - Dendritic cell phenotype can be improved by certain chemotherapies and is 
      associated with alterations to p21(waf1/cip1.).
PG  - 1553-61
LID - 10.1007/s00262-013-1456-0 [doi]
AB  - INTRODUCTION: Dendritic cells (DCs) possess the capacity to elicit immune 
      responses against harmful antigens and have been used in DC-vaccines to stimulate 
      the immune system to engage cancer cells. However, a lack of an appreciation of 
      the quality of the DC that is used and/or the monocyte from which it is derived 
      has limited their successful incorporation into treatment strategies. METHODS: In 
      the current study, we explored the relationship between cytokine receptor 
      expression on the monocytes and its subsequent development into DCs. The 
      significance of p21 expression in DCs during differentiation was also studied, as 
      was the effect that manipulating this with chemotherapy may have on DC quality. 
      RESULTS: DCs separated into two groups based on their ability to respond to a 
      maturation stimulus. This quality correlated with a particular receptor profile 
      of granulocyte-macrophage colony-stimulating factor and interleukin 4 expressed 
      on the monocytes from which they were derived. DC quality was also associated 
      with p21 expression, and artificially increasing their levels in DCs by using 
      some chemotherapy improved function. CONCLUSIONS: Overall, these studies have 
      highlighted a role for common chemotherapy in activating p21 in DCs, which is a 
      prerequisite for good DC function.
FAU - Liu, Wai Man
AU  - Liu WM
AD  - Division of Clinical Sciences, Department of Oncology, St George's, University of 
      London, 2nd Floor, Jenner Wing, London, SW17 0RE, UK, w.liu@sgul.ac.uk.
FAU - Scott, Katherine Ann
AU  - Scott KA
FAU - Thompson, Mareike
AU  - Thompson M
FAU - Dalgleish, Angus George
AU  - Dalgleish AG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130704
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Cell Differentiation/immunology
MH  - Cyclin-Dependent Kinase Inhibitor p21/biosynthesis/*immunology
MH  - Dendritic Cells/*cytology/*immunology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Immunotherapy
MH  - Interleukin-4/pharmacology
MH  - Monocytes/cytology/drug effects/immunology
MH  - Neoplasms/*drug therapy/*immunology
MH  - Phenotype
PMC - PMC11029784
COIS- Wai Man Liu, Katherine Ann Scott, and Mareike Thompson declare that they have no 
      conflict of interest. Angus George Dalgleish has acted as an advisor for, and 
      holds a research grant from Celgene Corp.
EDAT- 2013/07/05 06:00
MHDA- 2014/05/06 06:00
PMCR- 2013/07/04
CRDT- 2013/07/05 06:00
PHST- 2013/05/13 00:00 [received]
PHST- 2013/06/27 00:00 [accepted]
PHST- 2013/07/05 06:00 [entrez]
PHST- 2013/07/05 06:00 [pubmed]
PHST- 2014/05/06 06:00 [medline]
PHST- 2013/07/04 00:00 [pmc-release]
AID - 1456 [pii]
AID - 10.1007/s00262-013-1456-0 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2013 Oct;62(10):1553-61. doi: 
      10.1007/s00262-013-1456-0. Epub 2013 Jul 4.